Facilitating Efficient Clone Selection And Enabling High-Throughput Clarification And Purification Processes

By Ivo Bakker, Dora Szegvari, João Henrique P. M. Santos, Lenneke de Winter, Catalina Suarez Ruiz, James Edwards

Explore the integration of the Ambr® 15 bioreactor and StreamLink® CC 15 purification system to streamline clone selection and bioprocessing for biotherapeutics. With biopharmaceuticals rising in demand, companies need faster, more cost-effective workflows for early-stage development. Ambr® 15 enables high-throughput culturing of multiple clones under controlled conditions, supporting real-time monitoring of cell growth and metabolic profiles. This data helps identify promising clones for downstream processing.

StreamLink® CC 15 automates sample clarification and Protein A-based purification, reducing operator intervention and the risk of human error. Using the system, 21 IgG1-producing CHO cell lines were processed, achieving recoveries ranging from 48.5% to 73.7%—with optimization, yields could potentially exceed 90%. Quality attributes such as glycan profiles and charge variants were comparable to results obtained through traditional methods.

The combined system provides several advantages: it reduces manual labor by 60%, ensures real-time process monitoring, and offers high consistency in output. These benefits make the workflow ideal for expediting the transition from development to clinical production. With automated, high-throughput capabilities, the Ambr® 15 and StreamLink® CC 15 systems provide a powerful tool for accelerating the timeline for developing biotherapeutics.